Yahoo Web Search

Search results

1. • 

     ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime

     Benzinga via Yahoo Finance· 1 year ago

     The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer...

2. • 

     Novartis (NVS) Kisqali Positive for Early Breast Cancer

     Zacks via Yahoo Finance· 1 year ago

     Novartis AG NVS announces positive top-line results from an interim analysis of late-stage NATALEE...

3. • 

     U.S. cancer centers report ongoing shortage of chemotherapy drugs

     United Press International via Yahoo News· 6 months ago

     U.S. cancer centers continue to have shortages of commonly used chemotherapy drugs, a new survey...

4. • 

     Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use

     Zacks via Yahoo Finance· 1 year ago

     The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in...

5. • 

     What the Chemotherapy Drug Shortage Means for Patient Care

     Health via Yahoo News· 10 months ago

     More than 90% of the nation’s top cancer centers have been affected by a shortage of chemotherapy...

6. • 

     Seagen Inc. (NASDAQ:SGEN) Q4 2022 Earnings Call Transcript

     Insider Monkey via Yahoo Finance· 1 year ago

     Seagen Inc. (NASDAQ:SGEN) Q4 2022 Earnings Call Transcript February 15, 2023 Operator: Good day...

7. • 

     Invitae (NVTA) Q2 2023 Earnings Call Transcript

     Motley Fool· 8 months ago

     Hosting the call today is our president and CEO, Ken Knight. In hereditary cancer, guideline expansions and better outcomes are expected to further...

8. • 

     ChatGPT Caught Giving Horrible Advice to Cancer Patients

     Futurism via Yahoo News· 8 months ago

     Over the last year, it seems as if everybody is trying to stuff artificial intelligence technologies...

9. • 

     Clinical pathways are the currency of health tech

     TechCrunch ExtraCrunch· 9 months ago

     As healthcare becomes more entrenched in the digital revolution, the need for an approved set of protocols for care delivery — clinical pathways — is...

10. • Invitae Stock Soars 277% in a Day: Time to Buy?

      Motley Fool· 2 years ago

      For medical genetics specialist Invitae's (NYSE: NVTA) downtrodden investors, there was a lot riding on the company's second-quarter earnings release. An 85% share decline year to date can impart ...